Searched for
DAIICHI SANKYO EARNINGS
AstraZeneca, Daiichi Drug gets broad tumor approval in USEnhertu, a collaboration between AstraZeneca and Daiichi Sankyo, gains FDA approval for treating HER2-positive solid tumors spread througho...- Nikkei hits over 7-month high on Wall Street optimism, robust earningsInvestors appeared to show scant response to data that signalled Japan's economy rebounded at a slower-than-expected pace in the second qua...
- Japan stocks end higher on gains in drugmakers, tech stocksThe Nikkei 225 Index rose 0.33 per cent to 26,524.79, while the broader Topix rose 0.23 per cent to 1,765.21.
- Sun Pharma jumps as subsidiary Taro reports healthy March quarter numbers“It is a sentiment booster for Sun Pharma. One can expect may be a 3-5 per cent uptick on the stock,” Jani said. The stock rose 4.32 per ce...
- Sun Pharma sees biggest fall in 5 yearsThe counter witnessed one of the largest secondary market transactions when Daiichi Sankyo sold about 215 million shares in Sun Pharma via ...
- Japan's Daiichi Sankyo set to sell its entire 9% stake in Sun Pharma for Rs 18,000 croreDaiichi Sankyo will exit from Sun Pharma by selling its 9% stake it owns in it for Rs 18,000 crore in block trades in the stock market.
- Ranbaxy-Sun Pharma merger deal may close by 2014 end: Daiichi SankyoThe $4 billion merger deal of Ranbaxy with Sun Pharma is expected to close by the end of 2014, Japanese drug maker Daiichi Sankyo said.
- Market gives a thumbs-up to Ranbaxy deal; Sun Pharma and Daiichi Sankyo gainShares of Sun Pharma surged 2.68 per cent or Rs 15.35 to close at Rs 587.25 as the all-share deal’s swap ratio is seen to favour investors ...
- Ranbaxy surprises street with Q4 loss of Rs 492 croreThe Gurgaon-based firm has provisioned Rs 186 crore to deal with the costs arising out of the product recall.
- Almost four years after Daiichi Sankyo's acquisition, Ranbaxy back on track with low-cost version of LipitorRanbaxy has started exporting a low-cost version of cholesterol-lowering blockbuster Lipitor to the US from its new facility in Mohali in P...
- Daiichi Sankyo reports Q3 net loss of $255 millionDaiichi Sankyo suffered a net loss of $255 million in the Octr-Dec quarter of 2011 due to a strong yen and one-time charges related to Ranb...
- Ranbaxy Laboratories may pay $500m to settle disputes in USRanbaxy announced a $500-million provision to resolve potential civil and criminal liabilities arising out of an investigation by the US go...
- Ranbaxy settles issue with USFDA, to pay up to USD 500 mnRanbaxy has reached an agreement with the US health regulator to lift a ban on import of drugs from its certain factories in India.
- Daiichi swings to profit of $43 mn in Apr-Dec periodJapanese drug maker Daiichi Sankyo today said it has swung into a profit of 39.24 billion yen (about USD 43 million) for the April-December...
- Dip in Novelis’ goodwill may hit Hindalco’s profitTwo years after its high-profile Novelis acquisition, which catapulted Hindalco to the world’s fifth-largest aluminium maker’s slot, the Ad...
- Daiichi may book non-cash loss of $3.9 bn on Ranbaxy buy in Q3Japan’s Daiichi Sankyo, the new owner of India’s largest drugmaker Ranbaxy Laboratories, expects a non-cash valuation loss of $3.9 billion ...
- Daiichi sees $3.9 bn loss on Ranbaxy buyJapan's Daiichi Sankyo, the new owner of India's largest drugmaker Ranbaxy Laboratories expects a non-cash valuation loss of $3.9 billion o...
- The Ranbaxy model and consolidation in pharma sectorThe incipient process of consolidation in pharma sector could lead to enhanced market power & reduced competition, which in turn would rais...
- STCI Cap assigns 'underperformer' to Ranbaxy; target Rs 503STCI Capital Markets Research has changed their recommendation to ‘underperformer’ on Ranbaxy Laboratories with a price target of Rs 503.
- Religare maintains buy on GSK Pharma, Sujana TowersReligare Securities has maintained 'buy' on GlaxoSmithKline Pharma with a target price of Rs 1,192 based on 20 times CY09E earnings.
Load More
